drugset / Trial / NCT06429930
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
RandomizedSingle-groupDouble-blindTreatment
Summary
This is the second single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 15 μg to 30 μg.
Timeline
- Start
- 2025-04-11
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iloprost | Other / unclassified | 15 ug | Inhaled |
| Subject | Iloprost | Other / unclassified | 30 ug | Inhaled |